FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 8933 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| Randomized phase II trial of chemoradiotherapy with S-1 versus combination chemotherapy with gemcitabine and S-1 as neoadjuvant treatment for resectable pancreatic cancer (JASPAC 04). PMID 37746781 · J Hepatobiliary Pancreat Sci · 2023-Nov 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| A randomized trial to evaluate the preventive effect of lafutidine on chemotherapy-induced peripheral neuropathy in patients treated with carboplatin and paclitaxel for lung cancer. PMID 37731302 · Ann Palliat Med · 2023-Nov The record describes a randomized trial in lung cancer patients, but it is not a definitive Phase III/IIIb or Phase II/III efficacy trial. It is a small, single-center study primarily evaluating a toxicity endpoint (CIPN prevention), with a sample size target of ~40 and actual enrollment of 16. The primary endpoint is the incidence of grade ≥2 peripheral neuropathy, not a standard efficacy endpoint like OS or PFS. While PFS is mentioned, it is a secondary or exploratory endpoint in this context. The study is therefore not eligible for the oncology Kaplan-Meier digitization cohort. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Upfront liquid next-generation sequencing in treatment-naïve advanced non-small cell lung cancer patients: A prospective randomised study in the Taiwanese health system. PMID 37722270 · Eur J Cancer · 2023-Nov The study is a randomized trial in oncology with time-to-event endpoints, but the trial phase is not explicitly stated as Phase III/IIIb or Phase II/III, and the intervention is diagnostic/timing of genomic testing rather than a clear drug-containing intervention. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| [177Lu]Lu-PSMA-617 Versus Docetaxel in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: Final Survival Analysis of a Phase 2 Randomized, Controlled Trial. PMID 37709534 · J Nucl Med · 2023-Nov 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Two web-based dynamically interactive nomograms and risk stratification systems for predicting survival outcomes and guiding treatment in non-metastatic nasopharyngeal carcinoma. PMID 37684510 · J Cancer Res Clin Oncol · 2023-Nov The record describes a retrospective prognostic nomogram development study using a registry database (SEER), not a Phase III or Phase II/III randomized controlled trial evaluating a drug intervention. While it includes time-to-event endpoints (OS, CSS) and analyzes chemotherapy as a variable, the study design is not a prospective randomized trial. The 'randomized' label in metadata refers only to the random split of the cohort for model development, not a trial randomization. Therefore, it does not meet the core eligibility criteria for a definitive trial report with a drug-containing intervention. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Topotecan clearance based on a single sample and a population pharmacokinetic model: Application to a pediatric high-risk neuroblastoma clinical trial. PMID 37664968 · Pediatr Blood Cancer · 2023-Nov The abstract describes a pharmacokinetic modeling study that applies a method to data from a pediatric Phase III neuroblastoma trial (ANBL0532). However, the reported results (toxicity, early response) are not the primary/key secondary time-to-event efficacy endpoints required (e.g., OS, PFS, DFS). The abstract does not mention Kaplan-Meier curves, hazard ratios, or any survival/recurrence analysis. Therefore, it fails the time_to_event criterion. Randomization status is also not explicitly confirmed in this pharmacokinetic context, though the source trial is described as Phase III. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Maintenance strategies after anti-EGFR-based induction in metastatic colorectal cancer: A systematic review and bayesian network meta-analysis. PMID 37659764 · Crit Rev Oncol Hematol · 2023-Nov 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| The Tissue Systems Pathology Test Outperforms Pathology Review in Risk Stratifying Patients With Low-Grade Dysplasia. PMID 37657759 · Gastroenterology · 2023-Nov This is a blinded cohort study within a randomized controlled trial, comparing the performance of a diagnostic tissue test (TSP-9) to pathology review for risk stratification in Barrett's esophagus. It does not involve a drug intervention and does not report a standard time-to-event efficacy endpoint (e.g., OS, PFS, DFS) for a therapeutic agent. The progression endpoint (to HGD/EAC) is reported as a proportion with median time, not as a formal time-to-event analysis with KM/HR. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Oncological outcomes of standard versus prolonged time to surgery after neoadjuvant chemoradiotherapy for oesophageal cancer in the multicentre, randomised, controlled NeoRes II trial. PMID 37657554 · Ann Oncol · 2023-Nov 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Prognostic analysis and treatment utilization of different treatment strategies in elderly esophageal cancer patients with distant metastases: a SEER database analysis. PMID 37644234 · J Cancer Res Clin Oncol · 2023-Nov 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Construction of the survival nomograms for colon cancer patients of different ages based on the SEER database. PMID 37639008 · J Cancer Res Clin Oncol · 2023-Nov The study is a retrospective prognostic modeling study using SEER database data to construct nomograms. It is not a randomized controlled trial testing a drug intervention. Although it involves human oncology and random patient assignment for model training, it lacks a drug intervention, a phase designation for a trial, and a time-to-event efficacy endpoint for a treatment comparison. Therefore, it does not meet the eligibility criteria. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| A novel postoperative nomogram and risk classification system for individualized estimation of survival among patients with parotid gland carcinoma after surgery. PMID 37633867 · J Cancer Res Clin Oncol · 2023-Nov Study is an observational, non-randomized, retrospective cohort analysis (using SEER database) developing a prognostic nomogram. It lacks a randomized trial design and a Phase III/IIIb or Phase II/III drug intervention. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Neoadjuvant carboplatin in triple-negative breast cancer: results from NACATRINE, a randomized phase II clinical trial. PMID 37578666 · Breast Cancer Res Treat · 2023-Nov 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Effect of duration of adjuvant chemotherapy with S-1 (6 versus 12 months) for resected pancreatic cancer: the multicenter clinical randomized phase II postoperative adjuvant chemotherapy S-1 (PACS-1) trial. PMID 37552354 · Int J Clin Oncol · 2023-Nov 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Endoscopic Ultrasound-Guided Biliary Drainage of First Intent With a Lumen-Apposing Metal Stent vs Endoscopic Retrograde Cholangiopancreatography in Malignant Distal Biliary Obstruction: A Multicenter Randomized Controlled Study (ELEMENT Trial). PMID 37549753 · Gastroenterology · 2023-Nov 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| Pharmacokinetics and Pharmacodynamics of Burixafor Hydrobromide (GPC-100), a Novel C-X-C Chemokine Receptor 4 Antagonist and Mobilizer of Hematopoietic Stem/Progenitor Cells, in Mice and Healthy Subjects. PMID 37539772 · Clin Pharmacol Drug Dev · 2023-Nov The study is a Phase I, randomized, controlled trial in healthy volunteers evaluating the pharmacokinetics, pharmacodynamics, and safety of burixafor for hematopoietic stem cell mobilization. It is not a cancer treatment trial, does not report a Phase III or definitive trial phase, and lacks any primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS). Therefore, it is ineligible. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Managing Cardiovascular and Cancer Risk Associated with JAK Inhibitors. PMID 37490213 · Drug Saf · 2023-Nov 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Analysis of lncRNAs profiles associated with ferroptosis can predict prognosis and immune landscape and drug sensitivity in patients with clear cell renal cell carcinoma. PMID 37477388 · J Biochem Mol Toxicol · 2023-Nov This record is a retrospective bioinformatics study analyzing public genomic data to develop a prognostic signature. It is not a report of a randomized clinical trial of a therapeutic intervention. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Robot-assisted versus three-dimensional laparoscopic radical prostatectomy: 12-month outcomes of a randomised controlled trial. PMID 37461186 · BJU Int · 2023-Nov 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| Impairment of health-related quality of life for children with acute lymphoblastic leukemia over the first year of therapy: A report from the DFCI ALL Consortium. PMID 37461125 · Pediatr Blood Cancer · 2023-Nov 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 |
H
L
B
|
旧查询独有 | eligiblephase3_publication_type | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Phase II Randomized Trial of Carboplatin, Pemetrexed, and Bevacizumab With and Without Atezolizumab in Stage IV Nonsquamous Non-Small-Cell Lung Cancer Patients Who Harbor a Sensitizing EGFR Mutation or Have Never Smoked. PMID 37451930 · Clin Lung Cancer · 2023-Nov 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Personalised indocyanine-guided lymphadenectomy for prostate cancer: a randomised clinical trial. PMID 37410659 · BJU Int · 2023-Nov The study is excluded because it does not involve a drug-containing intervention (it compares surgical techniques). Furthermore, the primary endpoint is safety, and the time-to-event endpoint (BCR-free survival) is not reported with formal time-to-event results (e.g., Kaplan-Meier curves, hazard ratios) in the abstract. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Upadacitinib in patients with psoriatic arthritis and inadequate response to biologics: 3-year results from the open-label extension of the randomised controlled phase 3 SELECT-PsA 2 study. PMID 37404160 · Clin Exp Rheumatol · 2023-Nov The study is a randomized controlled Phase III trial with a drug intervention and long-term results, but it evaluates upadacitinib for psoriatic arthritis (a rheumatologic condition), not a human malignant neoplasm. Therefore, it does not meet the oncology requirement. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Durvalumab in Combination With Olaparib Versus Durvalumab Alone as Maintenance Therapy in Metastatic NSCLC: The Phase 2 ORION Study. PMID 37390980 · J Thorac Oncol · 2023-Nov 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| A prognostic model for predicting progression-free survival in patients with advanced non-small cell lung cancer after image-guided microwave ablation plus chemotherapy. PMID 37318606 · Eur Radiol · 2023-Nov The study is a secondary analysis (prognostic model development) using data from a prior RCT, not a formal primary result report of a definitive phase trial. The phase of the underlying trial is not explicitly confirmed as Phase III/IIIb or Phase II/III in the metadata. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Development and validation of a prognostic model based on metabolic risk score to predict overall survival of endometrial cancer in Chinese patients. PMID 37293802 · J Gynecol Oncol · 2023-Nov The record describes a retrospective prognostic model development study for endometrial cancer, not a randomized controlled trial of a drug intervention. Although it includes OS as a time-to-event endpoint, it does not meet the core eligibility criteria of being a Phase III/IIIb or Phase II/III randomized trial with a drug-containing intervention and a primary/key secondary efficacy endpoint. The 'Randomized Controlled Trial' publication type appears to be misapplied, referring to the random division of the study cohort into training and validation groups, not to a randomized trial of a therapeutic intervention. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| A randomized controlled trial investigating rectus sheath catheters following radical cystectomy. PMID 37259473 · BJU Int · 2023-Nov The study is a randomized, controlled, original result trial in an oncology (bladder cancer) setting, but it compares two anesthetic/analgesic techniques (rectus sheath catheter vs. thoracic epidural) and does not involve a systemic drug intervention as a study arm. The primary endpoint is cumulative opiate use, which is not a time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP). |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Effect of sinus resection combined with vacuum-assisted closure on sacrococcygeal pilonidal sinus. PMID 37218401 · Int Wound J · 2023-Nov The study is a randomized controlled trial comparing surgical techniques for sacrococcygeal pilonidal sinus, which is not a human malignant neoplasm. It does not involve a drug-containing intervention, and its primary endpoints are perioperative indicators, clinical efficacy (ORR), pain, complications, and recurrence rates, not a time-to-event efficacy endpoint like OS, PFS, or DFS. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Relationship Between Baseline Prostate-specific Antigen on Cancer Detection and Prostate Cancer Death: Long-term Follow-up from the European Randomized Study of Screening for Prostate Cancer. PMID 37088597 · Eur Urol · 2023-Nov The record describes a randomized screening trial (ERSPC) analyzing prostate-specific antigen (PSA) levels and prostate cancer mortality. It is a human oncology randomized controlled trial with long-term follow-up. However, it fails key eligibility criteria: 1) There is no drug-containing intervention (screening with PSA testing is not a drug intervention); 2) The phase is not explicitly stated as Phase III or equivalent; 3) While prostate cancer-specific mortality is a time-to-event outcome, the trial does not evaluate a drug therapy's effect on this endpoint, which is required for the cohort. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Evaluating awareness of skin cancer in skin of color organ transplant recipients. PMID 35871186 · Arch Dermatol Res · 2023-Nov The study is a randomized cross-sectional survey assessing skin cancer awareness, not a randomized controlled trial of a drug intervention with a time-to-event efficacy endpoint. It does not meet the core eligibility criteria for an oncology Kaplan-Meier digitization cohort. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Preoperative steroid for enhancing patients' recovery after head and neck cancer surgery with free tissue transfer reconstruction: protocol for a phase III, placebo-controlled, randomised, double-blind study (J-SUPPORT 2022, PreSte-HN Study). PMID 37258074 · BMJ Open · 2023-May-31 方案论文未报告临床试验结果。 |
H
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Conventional partial pancreatoduodenectomy versus an extended pancreatoduodenectomy (triangle operation) for pancreatic head cancers-study protocol for the randomised controlled TRIANGLE trial. PMID 37254179 · Trials · 2023-May-30 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Effects of music therapy on anxiety in patients with cancer: study protocol of a randomised controlled trial. PMID 37247967 · BMJ Open · 2023-May-29 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Leveraging social media to increase lung cancer screening awareness, knowledge and uptake among high-risk populations (The INSPIRE-Lung Study): study protocol of design and methods of a community-based randomized controlled trial. PMID 37237339 · BMC Public Health · 2023-May-26 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| HELP - Heidelberg decision aid for lung cancer patients: a randomized controlled clinical trial. PMID 37231417 · Trials · 2023-May-25 The record describes a protocol for a randomized trial evaluating a decision aid intervention for lung cancer patients. It lacks a drug-containing intervention and a time-to-event efficacy endpoint (OS, PFS, etc.), and presents no results. Therefore, it does not meet the eligibility criteria. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| The prognostic value of radiomic features from pre- and post-treatment 18F-FDG PET imaging in patients with nasopharyngeal carcinoma. PMID 37231092 · Sci Rep · 2023-May-25 The record describes a retrospective prognostic biomarker study analyzing radiomic features from PET scans in patients with nasopharyngeal carcinoma. While it involves human oncology and time-to-event endpoints (PFS, OS), it does not meet the core eligibility criteria. It is not a report of a randomized trial of a drug-containing intervention. The publication type includes 'Randomized Controlled Trial', but the study design described in the abstract is retrospective and focused on imaging biomarker prediction, not a randomized comparison of drug therapies. There is no mention of a Phase III/IIIb or Phase II/III drug trial. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Effects of Semisupervised Exercise Training on Health Outcomes in People With Lung or Head and Neck Cancer: Protocol for a Randomized Controlled Trial. PMID 37223986 · JMIR Res Protoc · 2023-May-24 The record is a protocol for a randomized trial in oncology patients with a time-to-event endpoint (survival) and drug intervention context, but it does not report results, thus failing the original-result criterion. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Coping After Breast Cancer: Protocol for a Randomized Controlled Trial of Stress Management eHealth Interventions. PMID 37103493 · JMIR Res Protoc · 2023-May-24 This is a protocol for a randomized controlled trial of psychosocial eHealth interventions in breast cancer survivors. It is not an original result report, does not involve a drug-containing intervention, and does not focus on a primary time-to-event efficacy endpoint (e.g., OS, PFS, DFS). The phase is not specified as Phase III/IIIb or Phase II/III. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Durvalumab plus tremelimumab for the treatment of advanced neuroendocrine neoplasms of gastroenteropancreatic and lung origin. PMID 37221181 · Nat Commun · 2023-May-23 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Study protocol of an open-label, single arm phase II trial investigating the efficacy and safety of Trifluridine/Tipiracil combined with irinotecan as a second line therapy in patients with cholangiocarcinoma (TRITICC). PMID 37217885 · BMC Cancer · 2023-May-22 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Exercise effects on functional capacity and quality of life in older patients with colorectal cancer: study protocol for the ECOOL randomized controlled trial. PMID 37211611 · BMC Geriatr · 2023-May-22 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Postoperative effect of sufentanil preemptive analgesia combined with psychological intervention on breast cancer patients. PMID 37210488 · BMC Anesthesiol · 2023-May-20 This is a randomized trial of a drug (sufentanil) in breast cancer patients, but it is a perioperative analgesic study focused on pain outcomes (VAS scores, awakening time, time to first analgesic), not a cancer efficacy trial. It lacks a Phase III designation and does not report any primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS, HR, Kaplan-Meier curve). |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Prospective Randomized Trial of Docetaxel Versus Best Supportive Care in Patients With Non-Small-Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy. PMID 37196430 · J Clin Oncol · 2023-May-20 The record describes a randomized, drug-intervention trial in human oncology with primary time-to-event efficacy endpoints (OS, TTP). The phase is not explicitly stated in the provided metadata but is inferred as Phase III based on the trial design (randomized, control arm, survival endpoint, multi-center study type) and is consistent with the criteria for 'phase3_or_definitive'. All other required criteria are explicitly established in the abstract. |
B
|
影子组漏检补回 | eligiblemodel_adjudicated_eligible | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Efficacy and safety of LY01005 versus goserelin implant in Chinese patients with prostate cancer: A multicenter, randomized, open-label, phase III, non-inferiority trial. PMID 37010251 · Chin Med J (Engl) · 2023-May-20 The trial is an oncology Phase III randomized study of a drug intervention with original results. However, the primary and secondary efficacy endpoints are biomarker-based (testosterone suppression levels, PSA changes) and do not include the required time-to-event endpoints (OS, PFS, DFS, EFS, RFS, TTP) or Kaplan-Meier/HR analyses. Therefore, it does not meet the time-to-event criterion for eligibility. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Differential Efficacy From the Addition of Bortezomib to R-CHOP in Diffuse Large B-Cell Lymphoma According to the Molecular Subgroup in the REMoDL-B Study With a 5-Year Follow-Up. PMID 36972491 · J Clin Oncol · 2023-May-20 The record describes a phase III randomized trial with drug intervention and primary/key secondary time-to-event efficacy endpoints (PFS and OS). The abstract provides updated results from the original trial, fulfilling the criteria for an eligible record. The deterministic review flagged unclear randomization evidence, but the abstract explicitly states it is a 'phase III adaptive trial' comparing two arms, confirming randomization. |
B
|
影子组漏检补回 | eligiblemodel_adjudicated_eligible | confirmed 1 Figure · 6 Panel · risk visible |
| Efficacy of a Smoking Cessation Intervention for Survivors of Cervical Intraepithelial Neoplasia or Cervical Cancer: A Randomized Controlled Trial. PMID 36921237 · J Clin Oncol · 2023-May-20 This is a randomized trial in oncology survivors, but it fails multiple key eligibility criteria: it is not a Phase III/IIIb or Phase II/III trial of a drug intervention for cancer treatment, it does not report a time-to-event efficacy endpoint (OS, PFS, DFS, etc.) using Kaplan-Meier or HR, and its primary focus is a behavioral intervention for smoking cessation, not an anti-cancer drug therapy. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| A postsurgical prognostic nomogram for patients with lymph node positive rectosigmoid junction adenocarcinoma. PMID 37202718 · BMC Gastroenterol · 2023-May-18 The study is a retrospective prognostic model development and validation using a large database. It is not a randomized controlled trial of a drug intervention. The 'randomized' tag in the metadata likely refers to the random split of data into development/validation cohorts, not a clinical trial randomization. Therefore, it fails the key criteria of being a Phase III/IIIb or Phase II/III randomized trial with a drug-containing intervention. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| PRECYCLE: multicenter, randomized phase IV intergroup trial to evaluate the impact of eHealth-based patient-reported outcome (PRO) assessment on quality of life in patients with hormone receptor positive, HER2 negative locally advanced or metastatic breast cancer treated with palbociclib and an aromatase inhibitor or palbociclib and fulvestrant. PMID 37198674 · Trials · 2023-May-17 The study is a Phase IV randomized controlled trial with a drug intervention and a primary time-to-event endpoint (TTD). It is excluded because it is not Phase III/IIIb or Phase II/III, and it is a protocol without reported results. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| PET/CT reading for relapse in non-small cell lung cancer after chemoradiotherapy in the PET-Plan trial cohort. PMID 37198668 · Cancer Imaging · 2023-May-17 The study is a retrospective analysis of diagnostic accuracy for relapse detection using PET/CT within the PET-Plan trial cohort. While the parent trial (PET-Plan) is a randomized, multi-center study, this specific publication does not report any therapeutic efficacy endpoints (e.g., OS, PFS) or time-to-event outcomes. It evaluates imaging criteria, not drug intervention efficacy, and thus does not meet the core eligibility criteria for the oncology Kaplan-Meier digitization cohort. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Efficacy of focal high-dose-rate brachytherapy in the treatment of patients diagnosed with low or favourable: intermediate-risk prostate cancer-a protocol for a randomised controlled trial. PMID 37197816 · BMJ Open · 2023-May-17 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |